Altria
MO
$71.42
+2.94%
Altria Group is the dominant U.S. tobacco company, operating Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, and Helix Innovations, with the Marlboro brand commanding roughly 40% U.S. cigarette share and leading positions in smokeless tobacco and machine-made cigars. The company is a classic cash-generative consumer staples incumbent rather than a growth story, using its pricing power and cost discipline to fund one of the highest dividend yields in the S&P 500 while diversifying into reduced-risk products such as Njoy vaping and On nicotine pouches. The current investor debate centers on whether Altria's pricing-led earnings growth and 57-year dividend streak can offset persistent cigarette volume declines, with the July 2026 Q2 earnings miss and subsequent stock drop sharpening scrutiny on cash flow and balance sheet leverage. Recent headlines highlight a nearly 5% dividend raise and a 6.5%-plus yield as the core bull case, while bears point to declining volumes, a payout ratio above 100% of reported earnings, and the slow scaling of smoke-free alternatives.…
MO
Altria
$71.42
Related headlines
Investment Opinion: Should I buy MO Today?
We assign a Hold rating on Altria Group (MO). The core thesis is that the stock offers a high dividend yield of 7.2% and trades at a discount to peers, but faces structural volume declines and balance sheet risks that limit upside. The analyst consensus average target price is $70.00, implying 3.9% upside, with a range of $58.00 to $82.00. The mixed analyst ratings (UBS and B of A Buy, Citigroup Neutral, Barclays Underweight) reflect the uncertainty.
Supporting evidence includes a forward PE of 11.49x, which is well below the consumer staples sector average of 18-22x. Revenue grew 15.5% year-over-year in Q2 2026 to $6.111 billion, but this growth is largely pricing-driven and may not be sustainable. Profitability is strong with a net margin of 37.6% and operating margin of 51.3%, and free cash flow TTM of $8.303 billion covers the dividend. However, the payout ratio of 100.19% and negative equity are concerns. The implied upside to the average target is modest at 3.9%.
Key risks that could invalidate the thesis include a dividend cut if free cash flow remains weak, accelerated volume declines, and regulatory action on menthol. The rating would upgrade to Buy if the forward PE compresses below 10x or if smoke-free products show meaningful traction, and downgrade to Sell if revenue growth turns negative or the dividend is cut. Relative to its own history, the trailing PE of 14.03x is near the upper end of its recent range (8-14x), suggesting the stock is fairly valued, not deeply undervalued. The high yield provides support, but total return potential is limited without a re-rating catalyst.
Sign up to view all
MO 12-Month Price Forecast
Altria presents a classic income versus risk trade-off. The 7.2% dividend yield and low beta make it attractive for income-focused investors, but the 100% payout ratio and negative equity raise concerns about dividend sustainability. The stock trades at a discount to peers, but near the upper end of its own recent PE range, suggesting limited multiple expansion potential. The Q2 earnings miss and negative free cash flow in the quarter highlight the challenges. We would upgrade to bullish if free cash flow recovers strongly and smoke-free products show accelerating adoption; we would downgrade to bearish if the dividend is cut or regulatory action intensifies.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Altria's 12-month outlook, with a consensus price target around $70.00 and implied upside of -2.0% versus the current price.
Average Target
$70.00
0 analysts
Implied Upside
-2.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$58 - $82
Analyst target range
Altria is covered by 11 analysts with a consensus average target price of $70.00, implying approximately +3.9% upside from the current price of $67.35. The recommendation field is listed as "none," but the institutional ratings data shows a mixed picture: UBS and B of A Securities maintain Buy ratings, Citigroup is Neutral, and Barclays is Underweight, with no recent upgrades or downgrades in the past six months. The consensus leans neutral-to-slightly-bullish, with the average target only modestly above the current price and the stock having underperformed the S&P 500 by 12.58 percentage points over the past year, suggesting analysts see limited near-term catalysts. The target range spans from a low of $58.00 to a high of $82.00, a spread of $24.00 or roughly 41% of the low target, which signals meaningful disagreement about the company's trajectory. The high target of $82.00 implies roughly +21.8% upside and would require either multiple expansion (forward PE rising from 11.49x toward 13-14x) or faster-than-expected earnings growth from smoke-free products and pricing, while the low target of $58.00 implies -13.9% downside and likely prices in accelerating volume declines, margin compression from regulatory pressure, or a dividend cut risk. The wide spread, combined with the stock's low beta of 0.494 and high short ratio of 4.52, suggests that while the stock is not heavily shorted, there is significant uncertainty about the terminal value of the cigarette business; the lack of recent rating changes indicates analysts are in a wait-and-see mode ahead of clarity on regulatory action and smoke-free product traction.
Bulls vs Bears: MO Investment Factors
The bear case currently has stronger evidence due to the Q2 earnings miss, negative free cash flow in the quarter, and a payout ratio above 100% of earnings. However, the bull case rests on a 7.2% dividend yield, a 57-year dividend growth streak, and a deep valuation discount that may already price in many risks. The most important tension is whether Altria's pricing power can continue to offset accelerating cigarette volume declines without straining the balance sheet. If volume declines moderate or smoke-free products scale faster, the stock could re-rate; if not, the dividend may be at risk. The low beta and defensive nature provide some cushion, but the stock is not a growth story.
Bullish
- Dividend yield near 7.2%: Altria offers a dividend yield of 7.20%, one of the highest in the S&P 500, backed by a 57-year streak of annual increases. The company recently raised its quarterly dividend by nearly 5%, signaling confidence in cash flow generation despite volume headwinds.
- Deep valuation discount to peers: MO trades at a trailing PE of 14.03x and forward PE of 11.49x, versus the consumer staples sector average of 18-22x. This 25-35% discount reflects regulatory and volume risks but provides a margin of safety if earnings stabilize.
- Exceptional profitability and cash flow: Q2 2026 net margin was 37.6% and operating margin 51.3%, well above typical staples peers. Free cash flow TTM of $8.303 billion comfortably covers the ~$7 billion annual dividend, though Q2 FCF turned negative due to timing.
- Defensive low-beta profile: With a beta of 0.494, MO is roughly half as volatile as the market, offering downside protection in turbulent markets. Its 7.2% yield and non-cyclical demand make it a classic defensive holding.
Bearish
- Payout ratio exceeds 100% of earnings: The payout ratio is 100.19% of reported earnings, meaning the dividend is not fully covered by net income. While free cash flow covers it, any sustained FCF weakness could jeopardize the dividend growth streak.
- Negative equity and high leverage: Debt-to-equity is -7.34 due to negative shareholders' equity, and the current ratio is a thin 0.606. This leveraged capital structure leaves little room for error if cash flows decline.
- Revenue concentration in combustibles: Smokeable products generated $5.392 billion of Q2 2026 revenue, versus $713 million from smokeless and just $6 million from other segments. The investment case remains almost entirely dependent on declining cigarette volumes.
- Recent earnings miss and stock drop: The July 2026 Q2 earnings miss triggered a sharp stock decline, with the shares falling from $74.92 on July 29 to $67.94 on July 30. This highlights sensitivity to any slowdown in pricing-led growth.
MO Technical Analysis
Altria is in a broad range-bound consolidation rather than a sustained trend, with a 1-year price change of just +2.43% and a year-to-date gain of +17.52% that has largely stalled since spring. At $67.35, the stock sits at roughly 56.6% of its 52-week range of $54.70 to $77.06, meaning it is in the middle of the band and neither near breakout highs nor deeply oversold lows. This positioning implies a market that is fairly valued on current fundamentals, with neither momentum-chasing buyers nor deep-value bargain hunters dominating the tape. Recent momentum has deteriorated: the 1-month change is -3.18% and the 3-month change is -7.37%, a clear deceleration from the strong 6-month gain of +2.42% and the +17.52% YTD advance. This negative short-term divergence against a positive longer-term trend signals a corrective pullback or mean reversion within an uptrend rather than a full trend reversal, especially given the stock's low beta of 0.494, which suggests the weakness is idiosyncratic (earnings-related) rather than market-driven. Relative strength confirms the lag: MO underperformed SPY by 3.77 percentage points over 1 month, 10.71 points over 3 months, and 14.93 points over 6 months, though it still leads SPY by 4.66 points YTD. Key technical levels are the 52-week low at $54.70 as major support and the 52-week high at $77.06 as resistance; a breakout above $77 would signal renewed accumulation and validate the dividend-growth narrative, while a breakdown below $54.70 would confirm a deeper downtrend and likely reflect fears over volume declines or balance sheet stress. With a beta of 0.494, the stock is roughly half as volatile as the market, which supports defensive position sizing but also means it will likely lag in strong risk-on rallies; the maximum drawdown of -18.58% over the period underscores that even low-beta staples can experience meaningful capital erosion.
Beta
0.46
0.46x market volatility
Max Drawdown
-17.9%
Largest decline past year
52-Week Range
$55-$77
Price range past year
Annual Return
+9.2%
Cumulative gain past year
| Period | MO Return | S&P 500 |
|---|---|---|
| 1m | +4.8% | +1.0% |
| 3m | -0.5% | +2.5% |
| 6m | +6.0% | +13.9% |
| 1y | +9.2% | +15.0% |
| ytd | +24.6% | +13.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MO Fundamental Analysis
Altria's revenue trajectory is modestly growing but uneven, with Q2 2026 revenue of $6.111 billion representing 15.52% year-over-year growth versus Q2 2025's $5.29 billion, though the sequential trend shows volatility from $5.079 billion in Q4 2025 to $5.428 billion in Q1 2026 and then $6.111 billion in Q2 2026. The segment mix is heavily concentrated: Smokeable Products generated $5.392 billion, Smokeless Products $713 million, and Other Segments just $6 million, meaning the investment case still rests almost entirely on combustibles despite the reduced-risk narrative. This concentration is a double-edged sword: pricing power in cigarettes continues to drive revenue, but any acceleration in volume declines or regulatory action on menthol or nicotine levels would directly hit the dominant segment, and the 15.5% YoY growth rate is unlikely to be sustainable given the structural decline in cigarette volumes. Profitability remains exceptional for a consumer staples company: Q2 2026 net income was $2.298 billion on $6.111 billion of revenue, a 37.6% net margin, with gross margin at 74.86% and operating margin at 51.32%. These margins are well above typical consumer staples levels (most packaged food and beverage peers operate in the 15-25% operating margin range), reflecting Altria's pricing power and asset-light brand model. However, the margin trend is mixed: gross margin improved from 64.59% in Q1 2026 to 74.86% in Q2 2026, but net margin compressed from 40.22% to 37.60%, and the Q4 2025 net margin was only 21.99% due to a $1.398 billion other-expense charge, highlighting earnings volatility from non-operating items. The balance sheet is the key risk: debt-to-equity is deeply negative at -7.34 due to negative shareholders' equity, the current ratio is a thin 0.606, and ROE is -198.37%, all symptomatic of a company that has returned so much capital via dividends and buybacks that book equity has been driven negative. Free cash flow TTM is $8.303 billion, which comfortably covers the roughly $7 billion annual dividend, but Q2 2026 free cash flow was -$147 million and operating cash flow was -$51 million, a sharp deterioration from Q1 2026's $2.231 billion FCF and $2.324 billion operating cash flow. The payout ratio of 100.19% of earnings and 7.20% dividend yield mean the dividend is covered by cash flow but leaves little margin for error if volumes decline faster than pricing can compensate; the company depends on consistent cash generation to service its leveraged capital structure, and any sustained FCF weakness would put the dividend growth streak at risk.
Quarterly Revenue
$6.1B
2026-06
Revenue YoY Growth
+15.5%
YoY Comparison
Gross Margin
74.9%
Latest Quarter
Free Cash Flow
$8.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MO Overvalued?
Because Altria is profitable with trailing net income of approximately $6.9 billion (derived from the $14.03 trailing PE and $96.7 billion market cap), the PE ratio is the appropriate primary valuation metric. The trailing PE is 14.03x versus a forward PE of 11.49x, an 18.1% discount that implies the market expects meaningful earnings growth over the next twelve months, consistent with analyst EPS estimates of $6.67 (which would represent roughly 35% growth from the trailing EPS of $0.0718, though that trailing figure appears distorted by non-recurring items). The forward PE of 11.49x is low in absolute terms and reflects the market's skepticism about the sustainability of earnings given volume declines and regulatory risk. On a peer comparison basis, Altria's trailing PE of 14.03x and forward PE of 11.49x are at a discount to the broader consumer staples sector, which typically trades in the 18-22x range, representing a roughly 25-35% discount. The PS ratio of 4.80x and EV/EBITDA of 10.89x are more in line with large-cap staples peers, but the PEG ratio of -0.38 is not meaningful due to negative or distorted earnings growth inputs. The discount to peers is justified by Altria's structural volume decline, regulatory overhang, negative book value, and ESG-related exclusion from many institutional portfolios, but the 7.20% dividend yield and 10.89x EV/EBITDA suggest the market is pricing in significant terminal risk. Historically, Altria's PE has ranged from a low of 5.21x in Q2 2024 to a high of 84.13x in Q3 2022 (distorted by a one-time charge), with more typical levels in the 8-14x range over the past three years; the current 14.03x trailing PE is near the upper end of that recent historical band. The PS ratio of 4.80x is well below the 14-22x range seen in 2022-2023, but that comparison is distorted by changes in share count and revenue recognition. Overall, the valuation is not stretched on an absolute basis, but it is toward the higher end of its own recent historical PE range, suggesting the market is pricing in a successful smoke-free transition and stable dividend growth rather than a value opportunity.
PE
14.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 5x~13x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.9x
Enterprise Value Multiple
Investment Risk Disclosure
Altria faces significant financial and operational risks stemming from its leveraged balance sheet and dependence on a declining product category. The debt-to-equity ratio is deeply negative at -7.34 due to negative shareholders' equity, and the current ratio of 0.606 indicates limited short-term liquidity. The payout ratio of 100.19% of earnings means the dividend is not covered by net income, relying instead on free cash flow, which turned negative in Q2 2026 at -$147 million. Additionally, revenue is heavily concentrated in smokeable products, which accounted for $5.392 billion of $6.111 billion in Q2 2026 revenue, exposing the company to regulatory actions such as menthol bans or nicotine caps.
Market and competitive risks include valuation compression if the stock's premium to its own history narrows, though it currently trades at a discount to peers. The forward PE of 11.49x is low, but the stock has underperformed the S&P 500 by 12.58 percentage points over the past year, reflecting investor skepticism. Regulatory headwinds, such as potential FDA restrictions on nicotine levels, could accelerate volume declines. The low beta of 0.494 means the stock is less sensitive to market swings, but it also lags in risk-on rallies. Competitive threats from illicit vaping products and other nicotine alternatives could further erode Altria's market share.
The worst-case scenario involves a perfect storm of accelerating cigarette volume declines, regulatory action on menthol, and a dividend cut. If volumes decline faster than pricing can compensate, free cash flow could deteriorate, forcing management to cut the dividend—a move that would likely trigger a sharp sell-off. The 52-week low is $54.70, representing a 18.8% downside from the current price of $67.35. The analyst low target of $58.00 implies 13.9% downside. In a severe scenario, the stock could test the 52-week low or lower, resulting in a loss of 19% or more from current levels.
FAQ
The most severe risk is a dividend cut, as the payout ratio is 100.19% of earnings and free cash flow turned negative in Q2 2026. Financial risks include negative equity (debt-to-equity of -7.34) and a thin current ratio of 0.606. Competitive risks include accelerating cigarette volume declines and competition from illicit vaping products. Regulatory risks include potential FDA action on menthol or nicotine levels, which could significantly impact revenue. Macro risks are lower due to the low beta of 0.494, but rising interest rates could increase debt costs. These risks are ranked from most to least severe: dividend sustainability, regulatory action, volume declines, and balance sheet leverage.
Our 12-month forecast has a base case (55% probability) with a target range of $65-$72, assuming volume declines remain in the 4-6% range and the dividend is maintained. The bull case (25% probability) targets $77-$82, driven by successful smoke-free product adoption and no adverse regulatory action. The bear case (20% probability) targets $54.70-$58.00, triggered by a dividend cut or accelerated volume declines. The most likely scenario is the base case, with the key assumption that pricing increases of 6-8% continue to offset volume declines. The analyst average target of $70.00 aligns with our base case.
MO trades at a trailing PE of 14.03x and a forward PE of 11.49x, which is a 25-35% discount to the consumer staples sector average of 18-22x. However, relative to its own history, the trailing PE is near the upper end of its recent 8-14x range. The PS ratio of 4.80x and EV/EBITDA of 10.89x are more in line with peers. The discount to peers is justified by regulatory risks, negative book value, and volume declines. The market appears to be pricing in a successful smoke-free transition and stable dividend growth, but not a value opportunity. Overall, the stock is fairly valued, with limited margin of safety.
MO offers a 7.2% dividend yield and trades at a forward PE of 11.49x, which is attractive for income investors. However, the payout ratio exceeds 100% of earnings, and the company faces structural volume declines in its core cigarette business. The analyst average target of $70.00 implies only 3.9% upside, suggesting limited near-term capital appreciation. The biggest downside risk is a dividend cut, which could drive the stock toward the 52-week low of $54.70. For risk-averse income investors, MO may be a good buy for the yield, but those seeking growth should look elsewhere. It is best suited for patient investors who can tolerate regulatory and volume risks.
MO is primarily a long-term income investment, not a short-term trading vehicle. Its low beta of 0.494 and high dividend yield of 7.2% make it suitable for buy-and-hold investors seeking steady income. The stock has a 57-year dividend growth streak, but the payout ratio above 100% and negative equity introduce long-term risks. Short-term traders may find opportunities around earnings or regulatory news, but the stock's low volatility limits quick gains. A minimum holding period of 3-5 years is recommended to ride out volume declines and potential regulatory changes. The dividend provides a significant portion of total return, so reinvesting dividends is key.